Dexcom (DXCM) Equity Ratio (2010 - 2026)

Dexcom (DXCM) has 17 years of Equity Ratio data on file, last reported at 0.45 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.45, up 32.78% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.45 (up 32.78% YoY), and the FY2025 annual result was 0.43, up 33.58% from the prior year.
• Equity Ratio rose to 0.45 in Q1 2026 per DXCM's latest filing, from 0.43 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.45 in Q1 2026 and troughed at 0.31 in Q2 2023.
• A 5-year average of 0.37 and a median of 0.36 in 2024 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2023 and 2025: Equity Ratio slipped 28.78% in 2023, then jumped 33.58% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.4 in 2022, then declined by 16.48% to 0.33 in 2023, then declined by 1.8% to 0.32 in 2024, then jumped by 33.58% to 0.43 in 2025, then gained by 2.92% to 0.45 in 2026.
• Business Quant data shows DXCM's Equity Ratio at 0.45 in Q1 2026, 0.43 in Q4 2025, and 0.36 in Q3 2025.